Atara Biotherapeutics, Inc. Income Statement
ATRA|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Atara Biotherapeutics, Inc. reported $121M in revenue and $33M in net income for FY2025. Revenue increased 1308.7% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -73.54 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $120.8M | $8.6M |
| SG&A Expense | $26.3M | $50.9M |
| R&D Expense | $37.4M | $224.8M |
| Operating Income | $35.9M | -$276.0M |
| Interest Expense | $3.8M | $5.3M |
| Income Tax | $31.0K | $15.0K |
| Net Income | $32.7M | -$276.1M |
| EPS (Basic) | -$11.41 | -$65.19 |
| EPS (Diluted) | -$11.41 | -$65.19 |
| Shares Outstanding | 5.9M | 4.3M |
| Operating Margin | 29.7% | -3219.5% |
| Profit Margin | 27.1% | -3220.9% |